BLOG

endpoints

Playing a surprisingly hot hand, BeyondSpring nails a $200M China deal in wake of a pivotal success

BeyondSpring announced this morning a commercialization and co-development agreement between its Chinese subsidiary Wanchunbulin and China’s Jiangsu Hengrui Pharmaceuticals.